EOLS - Evolus, Inc. Stock Analysis | Stock Taper
Logo

About Evolus, Inc.

https://www.evolus.com

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

David Moatazedi

CEO

David Moatazedi

Compensation Summary
(Year 2024)

Salary $743,750
Stock Awards $3,549,882
Option Awards $1,777,038
Incentive Plan Pay $900,000
All Other Compensation $28,207
Total Compensation $6,998,877
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Went public February 8, 2018
Method of going public IPO
Full time employees 372

ETFs Holding This Stock

Ratings Snapshot

Rating : C

Discounted Cash Flow 1
Return On Equity 5
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2

Most Recent Analyst Grades

Grade Summary

Buy 2
Outperform 1
Overweight 1
Hold 1

Showing Top 5 of 5

Price Target

Target High $19
Target Low $19
Target Median $19
Target Consensus $19

Institutional Ownership